ERBB2 and gastroesophageal junction adenocarcinoma: This antibody is currently commercialized by Roche for the treatment of HER2-positive breast cancer in the adjuvant and metastatic setting, and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma (Genentech 1998).